The global progesterone market size was estimated to be USD 1.16 billion in 2023 and is expected to reach at USD 4.53 billion by 2034 with a CAGR of 13.19% during the forecast period 2024-2034. The increasing occurrence of conditions such as abnormal uterine bleeding, menopause, endometrial cancer, hyperplastic precursor lesions, & amenorrhea among women, rising incidence of breast cancer, growing number of routinely monitored formulations, advancements in drug delivery systems, heightened awareness among patients, a greater emphasis on product development, and an uptick in the approval of innovative progesterone drugs are some of the key factors boosting the market growth.
An uptick in the approval of innovative progesterone drugs is predicted to boost the market growth during the forecast period. Progesterone, a naturally-occurring steroid hormone, is synthesized in the adrenal glands, ovaries, and placenta (during pregnancy). Its primary roles include sustaining pregnancy, managing the menstrual cycle, and supporting embryonic development. Inadequate progesterone levels can result in persistent breast tenderness, abdominal discomfort, fatigue, and may even contribute to miscarriage or fetal loss. To mitigate these risks, progesterone is administered to patients during this period. For instance, in July 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill, a progestin-only daily oral contraceptive, has received approval from the U.S. Food and Drug Administration (FDA) for over-the-counter (OTC) use across all age demographics.
By product, natural progesterone was the highest revenue-grossing segment in the global progesterone market in 2023 as its proven efficacy in generating a substantial volume of prescriptions, increasing prevalence of conditions such as abnormal uterine bleeding, breast or uterine cancer, & various health issues, growing inclination towards natural progesterone, surge in the introduction of new products. Additionally, synthetic progesterone is predicted to grow at the fastest CAGR during the forecast period owing to the broader accessibility & reduced expense relative to natural progesterone have resulted in an increased demand for synthetic progesterone in contraceptives and hormone replacement therapies. There is a rising trend in research & development efforts aimed at improving the effectiveness and safety of synthetic progesterone, growing acceptance of its use in treating gynecological disorders & supporting in vitro fertilization, and an uptick in regulatory approvals for synthetic progesterone. For instance, in November 2023, The combination of AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) has received approval in the United States for treating hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients exhibiting one or more biomarker alterations (PIK3CA, AKT1, or PTEN).
By mode of delivery, injectable was the highest revenue-grossing segment in the global progesterone market in 2023 owing to the rising advancements in technology, growing imperative to enhance patient outcomes. This type of technology is frequently employed in fertility treatments, especially in assisted reproductive technologies, and for the purpose of sustaining pregnancy. Injectable progesterone provides a controlled release mechanism and exhibits high bioavailability. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period owing to the rising desire for self-administration, an increase in research & development endeavors, and a surge in activities aimed at developing innovative oral tablets. For instance, in July 2023, ASKA Pharmaceutical Co., Ltd., a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., has commenced a Phase I/II clinical trial for the Relugolix Combination Tablet in Japan. The tablet was obtained through a licensing agreement with Takeda Pharmaceutical Company Limited.
By application, menopause was the highest revenue-grossing segment in the global progesterone market in 2023 owing to a substantial demographic representation of women aged between 45 and 59, coupled with an upward trend in the regulatory approval of new drugs designed for addressing menopausal symptoms. The administration of progesterone has proven effective in alleviating issues such as hot flashes and night sweats in women experiencing menopause. For instance, in May 2023, Veozah, a medication developed to alleviate symptoms like flushing and sweating in women with low estrogen levels, has received approval from the FDA. Additionally, regulation of the menstrual cycle, is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the number of women experiencing irregularities in their menstrual cycles, a rising prevalence of polycystic ovary syndrome (PCOS) or polycystic ovarian disease (PCOD), and an expanding awareness within the general population.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing consciousness regarding cancer diagnosis, an uptick in strategic initiatives among market players, including collaborative efforts aimed at strengthening their research & development capabilities, and an increase in the introduction of new products. For instance, in May 2022, Xiromed LLC has introduced a generic version of Progesterone Injection USP, 50 mg/mL, in the form of a Multiple-Dose Vial with a concentration of 500 mg/10 mL. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the number of women entering menopause is on the rise, and there is a growing incidence of kidney, breast, or uterine cancers. The population is increasingly embracing advanced treatment options, and there is a surge in obtaining approvals from regulatory authorities. For instance, in October 2022, Sun Pharma has obtained approval from the Subject Expert Committee (SEC) operating under the Central Drug Standard Control Organization (CDSCO) to produce and market sustained-release progesterone tablets (200/300/400mg) in India.
An uptick in the approval of innovative progesterone drugs is predicted to boost the market growth during the forecast period. Progesterone, a naturally-occurring steroid hormone, is synthesized in the adrenal glands, ovaries, and placenta (during pregnancy). Its primary roles include sustaining pregnancy, managing the menstrual cycle, and supporting embryonic development. Inadequate progesterone levels can result in persistent breast tenderness, abdominal discomfort, fatigue, and may even contribute to miscarriage or fetal loss. To mitigate these risks, progesterone is administered to patients during this period. For instance, in July 2023, Perrigo Company plc, a leading provider of Consumer Self-Care Products, announced that Opill, a progestin-only daily oral contraceptive, has received approval from the U.S. Food and Drug Administration (FDA) for over-the-counter (OTC) use across all age demographics.
By product, natural progesterone was the highest revenue-grossing segment in the global progesterone market in 2023 as its proven efficacy in generating a substantial volume of prescriptions, increasing prevalence of conditions such as abnormal uterine bleeding, breast or uterine cancer, & various health issues, growing inclination towards natural progesterone, surge in the introduction of new products. Additionally, synthetic progesterone is predicted to grow at the fastest CAGR during the forecast period owing to the broader accessibility & reduced expense relative to natural progesterone have resulted in an increased demand for synthetic progesterone in contraceptives and hormone replacement therapies. There is a rising trend in research & development efforts aimed at improving the effectiveness and safety of synthetic progesterone, growing acceptance of its use in treating gynecological disorders & supporting in vitro fertilization, and an uptick in regulatory approvals for synthetic progesterone. For instance, in November 2023, The combination of AstraZeneca's Truqap (capivasertib) and Faslodex (fulvestrant) has received approval in the United States for treating hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in adult patients exhibiting one or more biomarker alterations (PIK3CA, AKT1, or PTEN).
By mode of delivery, injectable was the highest revenue-grossing segment in the global progesterone market in 2023 owing to the rising advancements in technology, growing imperative to enhance patient outcomes. This type of technology is frequently employed in fertility treatments, especially in assisted reproductive technologies, and for the purpose of sustaining pregnancy. Injectable progesterone provides a controlled release mechanism and exhibits high bioavailability. Additionally, oral is predicted to grow at the fastest CAGR during the forecast period owing to the rising desire for self-administration, an increase in research & development endeavors, and a surge in activities aimed at developing innovative oral tablets. For instance, in July 2023, ASKA Pharmaceutical Co., Ltd., a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd., has commenced a Phase I/II clinical trial for the Relugolix Combination Tablet in Japan. The tablet was obtained through a licensing agreement with Takeda Pharmaceutical Company Limited.
By application, menopause was the highest revenue-grossing segment in the global progesterone market in 2023 owing to a substantial demographic representation of women aged between 45 and 59, coupled with an upward trend in the regulatory approval of new drugs designed for addressing menopausal symptoms. The administration of progesterone has proven effective in alleviating issues such as hot flashes and night sweats in women experiencing menopause. For instance, in May 2023, Veozah, a medication developed to alleviate symptoms like flushing and sweating in women with low estrogen levels, has received approval from the FDA. Additionally, regulation of the menstrual cycle, is predicted to grow at the fastest CAGR during the forecast period owing to the increase in the number of women experiencing irregularities in their menstrual cycles, a rising prevalence of polycystic ovary syndrome (PCOS) or polycystic ovarian disease (PCOD), and an expanding awareness within the general population.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing consciousness regarding cancer diagnosis, an uptick in strategic initiatives among market players, including collaborative efforts aimed at strengthening their research & development capabilities, and an increase in the introduction of new products. For instance, in May 2022, Xiromed LLC has introduced a generic version of Progesterone Injection USP, 50 mg/mL, in the form of a Multiple-Dose Vial with a concentration of 500 mg/10 mL. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the number of women entering menopause is on the rise, and there is a growing incidence of kidney, breast, or uterine cancers. The population is increasingly embracing advanced treatment options, and there is a surge in obtaining approvals from regulatory authorities. For instance, in October 2022, Sun Pharma has obtained approval from the Subject Expert Committee (SEC) operating under the Central Drug Standard Control Organization (CDSCO) to produce and market sustained-release progesterone tablets (200/300/400mg) in India.
Segmentation: Progesterone Market Report 2023 - 2034
Progesterone Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Synthetic Progesterone
- Natural Progesterone
Progesterone Market Analysis & Forecast by Mode of Delivery 2023 - 2034 (Revenue USD Bn)
- Suspended Form
- Injectable
- Oral
- Others
Progesterone Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Menopause
- Contraception
- Endometrial Cancer
- Dysfunctional Uterine Bleeding
- Hyperplastic Precursor Lesions
- Other
Progesterone Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Progesterone Market: Product Estimates & Trend Analysis
8. Progesterone Market: Mode Of Delivery Estimates & Trend Analysis
9. Progesterone Market: Application Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Progesterone Market
12. Europe Global Progesterone Market
13. Asia Pacific Global Progesterone Market
14. Latin America Global Progesterone Market
15. MEA Global Progesterone Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Cadila Pharmaceuticals
- Glenmark Pharmaceuticals
- Teva Pharmaceuticals
- Bionpharma
- Virtus
- Aquatic Remedies Pvt. Ltd
- Lupin
- Alkem Labs
- Estrellas Life Sciences Private Limited
- Cipla
- Bluebell Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.16 Billion |
| Forecasted Market Value ( USD | $ 4.53 Billion |
| Compound Annual Growth Rate | 13.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
